Lanreotide in Metastatic Enteropancreatic Neuroendocrine TumorsCAPLIN, Martyn E; PAVEL, Marianne; RINDI, Guido et al.The New England journal of medicine. 2014, Vol 371, Num 3, pp 224-233, issn 0028-4793, 10 p.Article

Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteersDREWE, J; SIEBER, C. C; MOTTET, C et al.Clinical pharmacology and therapeutics. 1999, Vol 65, Num 4, pp 413-419, issn 0009-9236Article

Effectiveness and tolerability of 3-year lanreotide Autogel® treatment in patients with acromegalyCARON, Philippe; COGNE, Muriel; RAINGEARD, Isabelle et al.Clinical endocrinology (Oxford. Print). 2006, Vol 64, Num 2, pp 209-214, issn 0300-0664, 6 p.Article

¹¹¹In- and ⁹⁰Y-DOTA-lanreotide: Results and implications of the MAURITIUS trialVIRGOLINI, Irene; BRITTON, Keith; BUSCOMBE, John et al.Seminars in nuclear medicine. 2002, Vol 32, Num 2, pp 148-155, issn 0001-2998Article

Effet antitumoral des analogues de la somatostatine dans les tumeurs neuroendocrines digestives = Antiproliferative effect of somatostatin analogs in neuroendocrine tumorsDE MESTIER, Louis; HENTIC, Olivia; BRIXI, Hedia et al.Hépato-gastro & oncologie digestive. 2014, Vol 21, Num 10, pp 835-844, issn 2115-3310, 10 p.Article

Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient dataTEMMERMAN, F; GEVERS, T; HO, T. A et al.Alimentary pharmacology & therapeutics. 2013, Vol 38, Num 4, pp 397-406, issn 0269-2813, 10 p.Article

Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)KHAN, M. S; EL-KHOULY, F; DAVIES, P et al.Alimentary pharmacology & therapeutics. 2011, Vol 34, Num 2, pp 235-242, issn 0269-2813, 8 p.Article

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegalyCHANSON, Philippe; BORSON-CHAZOT, Francoise; KUHN, Jean-Marc et al.Clinical endocrinology (Oxford. Print). 2008, Vol 69, Num 2, pp 299-305, issn 0300-0664, 7 p.Article

Home administration of lanreotide Autogel^® by patients with acromegaly, or their partners, is safe and effectiveBEVAN, J. S; NEWELL-PRICET, J; VISWANATH, A et al.Clinical endocrinology (Oxford. Print). 2008, Vol 68, Num 3, pp 343-349, issn 0300-0664, 7 p.Article

Effect of the somatostatin analogue lanreotide on meal-stimulated portal blood flow in patients with liver cirrhosisSCHIEDERMAIER, Peter; HARRISON, Phillip; ARTHUR, Michael et al.Digestion. 2002, Vol 65, Num 1, pp 56-60, issn 0012-2823Article

Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the management of acromegalyCARON, Ph; BECKERS, A; CULLEN, D. R et al.The Journal of clinical endocrinology and metabolism. 2002, Vol 87, Num 1, pp 99-104, issn 0021-972XArticle

Lanreotide labeled with ^99mTc: Preparation, preclinical testing and comparison with ¹¹¹In-DTPA-octreotideLAZNICEK, Milan; LAZNICKOVA, Alice; TREJTNAR, Frantisek et al.Anticancer research. 2002, Vol 22, Num 4, pp 2125-2130, issn 0250-7005, 6 p.Article

Influence du lanréotide sur la concentration sérique de prolactine chez les patients atteints de tumeurs somato-lactotropes = Effect of lanreotide on prolactin level in patients with pituitary mixed tumorsWASKO, R; SAWICKA, J; STACHOWIAK, C et al.Annales d'endocrinologie. 2002, Vol 63, Num 6, pp 532-535, issn 0003-4266, 4 p., 1Article

Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapyVIRGOLINI, I; PATRI, P; KURTARAN, A et al.Annals of oncology. 2001, Vol 12, pp 41-45, issn 0923-7534, SUP2Conference Paper

Somatostatin analogs for cancer treatment and diagnosis : An overviewSCARPIGNATO, Carmelo; PELOSINI, Iva.Chemotherapy (Basel). 2001, Vol 47, pp 1-29, issn 0009-3157, SUP2Article

Variable growth hormone profiles following withdrawal of long-term 30 mg slow-release lanreotide treatment in acromegalic patients : Clinical implicationsCARON, P; TABARIN, A; COGNE, M et al.European journal of endocrinology. 2000, Vol 142, Num 6, pp 565-571, issn 0804-4643Article

Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines : a preclinical studyTESEI, A; RICOTTI, L; DE PAOLA, F et al.Journal of chemotherapy. 2000, Vol 12, Num 5, pp 421-430, issn 1120-009XArticle

Slow-release lanreotide in the treatment of acromegaly: a study in 66 patientsVERHELST, Johan A; PEDRONCELLI, Alberto M; BEX, Mieke et al.European journal of endocrinology. 2000, Vol 143, Num 5, pp 577-584, issn 0804-4643Article

Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumorsJANSON, E. T; KÄLKNER, K. M; ERIKSSON, B et al.Nuclear medicine and biology. 1999, Vol 26, Num 8, pp 877-882, issn 0969-8051Article

A comparison of lanreotide and octreotide LAR for treatment of acromegalyTURNER, H. E; VADIVALE, A; KEENAN, J et al.Clinical endocrinology (Oxford. Print). 1999, Vol 51, Num 3, pp 275-280, issn 0300-0664Article

Somatostatin receptor ligands and their use in the treatment of endocrine disordersJANSON, E. T; ÖBERG, K.Current pharmaceutical design. 1999, Vol 5, Num 9, pp 693-705, issn 1381-6128Article

Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegalyTURNER, H. E; LINDSELL, D. R. M; VADIVALE, A et al.European journal of endocrinology. 1999, Vol 141, Num 6, pp 590-594, issn 0804-4643Article

Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinomaDAMGE, C; HAJRI, A.European journal of pharmacology. 1998, Vol 347, Num 1, pp 77-86, issn 0014-2999Article

Current experience with somatostatin analogues, especially angiopeptine, for the prevention of transplant vasculopathy in heart transplantationWAHLERS, T; OPPELT, P; PETHIG, K et al.Transplantation proceedings. 1998, Vol 30, Num 3, pp 866-867, issn 0041-1345Conference Paper

Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotideCARON, P; MORANGE-RAMOS, I; COGNE, M et al.The Journal of clinical endocrinology and metabolism. 1997, Vol 82, Num 1, pp 18-22, issn 0021-972XArticle